Faster clinical trial recruitment through direct patient access.
Piligrim combines an established medical patient base, a network of referring GPs and specialists, dedicated clinical-trial facilities and structured pre-screening workflows to shorten the path from study activation to enrolled patient.
Recruitment speed starts before the first patient is screened.
Piligrim is building recruitment around active patient access rather than waiting for eligible participants to find the study. Our model connects the site with general practitioners, specialists, existing medical populations and external healthcare partners.
Identify
Protocol-specific patient profiles are translated into practical referral criteria.
Refer
GPs, specialists and partner healthcare providers can direct potentially suitable patients to Piligrim.
Pre-screen
The site rapidly reviews key eligibility information before arranging a full screening visit.
Screen & Enrol
Qualified patients move into a coordinated consent, eligibility and investigator-review process.
One centre connecting patients, physicians and better-organised clinical trials.
Our focus is practical: realistic feasibility, predictable patient access, clear accountability and monitoring readiness.
Recruitment speed
An established patient base, 12 referring GPs and active specialist relationships create multiple recruitment channels from the moment a study opens.
Medical leadership
Oncology-led medical leadership and a multidisciplinary model involving suitable investigators and specialists.
Dedicated facilities
Ground-floor access, controlled reception, consultation rooms, participant areas and pharmacy capability.
Operational visibility
Protocol-driven management of visits, procedures, quality and financial events with traceable human oversight.
A leading focus in oncology, supported by broader access through our medical network.
Oncology and Clinical Haematology
Medical leadership, patient access and pharmacy expertise for complex studies, including investigational product handling and participant follow-up.
Additional Capabilities
Each study is assessed according to its protocol, investigator requirements and the available patient population.
Support throughout the operational study lifecycle.
From initial feasibility assessment to monitoring readiness and financial tracking.
Feasibility and Start-up
Assessment of patient population, investigator capacity, infrastructure and realistic recruitment potential.
Patient Identification
Access through the internal medical base, referring GPs, specialists and external partners.
Screening and Enrolment
A structured process for informed consent, eligibility review and investigator confirmation.
Visits and Documentation
Tracking of visit windows, procedures, source documents and missing activities.
Quality and Safety
Monitoring preparation, queries, protocol deviations and safety-process deadlines.
Financial Control
Linking completed visits and procedures to contractual financial events.
AI supports the team. Medical decisions remain with qualified professionals.
Piligrim is developing a proprietary, protocol-driven clinical research platform. It is designed to reduce manual work, identify gaps earlier and improve traceability.
In active pilot development
An environment designed for clinical work and participant comfort.
The centre is located on the ground floor of Poliklinika Bulgaria, with convenient access, professional clinical spaces and dedicated pharmacy expertise.
Information tailored to the way you want to work with Piligrim.
Patients
What a clinical trial is, how participation works and what your rights are.
Learn More For the Medical NetworkReferring Physicians
When and how a patient may be referred for preliminary assessment under a suitable protocol.
Referral Process For Medical ProfessionalsCareers and Partnerships
Opportunities for investigators, medical specialists, coordinators, nurses and pharmacists.
Explore Our Capabilities For Strategic PartnersInvestors
A clinical research centre, patient access and a proprietary technology product with growth potential.
Investment PerspectivePlanning a new clinical trial in Bulgaria?
Send us a short overview of the therapeutic area, phase and target population. Our team will arrange an initial discussion and provide a realistic feasibility assessment.
Pre-publication note: confirm that the figures 26,000+, 12 GPs, 766 m² and the stated Phase II–IV capability are current and supportable.